EUCTR2014-001276-56-IT进行中（未招募）1 期
A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatment with oral linezolid for complicated skin and skin structure infections (cSSSI) caused by Methicillin resistant Staphylococcus aureus (MRSA).
orth Bristol NHS - Southmead Hospital0 个研究点目标入组 225 人开始时间: 2014年6月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients will be enrolled in this study only if they meet all of the following numbered criteria:
- •1.Hospitalised with clinical evidence of at least 1 of the following MRSA infections:
- •First or second degree burns of less than 20% of body surface area with concomitant signs of cellulitis (excluding third degree burns and burns >20% of body surface area)
- •Major abscess (see exclusion criteria for qualifications)
- •Deep or extensive cellulitis, and/or
- •Wounds – trauma or post surgical
- •2.Presence of purulent or seropurulent drainage or at least 3 of the following signs and symptoms:
- •Drainage and/or discharge
- •Erythema (extending at least 1 cm beyond a wound edge)
- •Swelling and/or induration
- •Heat and/or localized warmth
- •Pain and/or tenderness to palpation
- •3.At least 1 of the following conditions considered to be pathogen-related:
- •Fever (temperature >38?C/100.4?F orally, rectally, or tympanically),
- •Elevated total peripheral white blood cells (WBCs) >10,000/mm3, or
- •>15% immature neutrophils (bands), regardless of total peripheral WBC count
- •4.Accessible infection site for culture or a bacteraemia where a culture cannot be obtained from the site of infection
- •5.Adult at least 18 years of age
- •6.Written informed consent to participate in the study before any study-specific procedures are performed
- •7.If of childbearing potential, must be using, or be prepared to use, a mechanical method of contraception (e.g. condom) during the study.
- •8.If female, has a negative serum pregnancy test (serum beta-human Chorionic Gonadotropin (hCG)) result immediately prior to enrolment. If obtaining the serum pregnancy result would cause a delay in treatment, the patient can be entered on the basis of a negative urine pregnancy test result. The urine pregnancy test must be sensitive to at least 50 mU/mL of beta-hCG, pending results of the serum test. The patient must end study medication therapy if the subsequent serum pregnancy test is positive
- •Patients who have received an antibiotic for a cSSSI but have not responded and are considered a failure on that treatment regimen are eligible for this study provided they have a positive MRSA baseline culture.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following will exclude a patient from enrolment into the study.
- •1.Women who are pregnant or breast-feeding
- •2.Pre menopausal women who refuse to substitute oral contraception during treatment by contraception using mechanical means (e.g. condom)
- •3.Known or suspected hypersensitivity to linezolid, minocycline or rifampicin
- •4.Clinical or laboratory evidence of significant impairment of hepatic function, i.e. bilirubin of >3x upper limit of normal range, AST or ALT >5x upper limit of normal range, proven histological liver changes on biopsy
- •5.Major abscess associated with diabetic foot conditions
- •6.Suspected or confirmed osteomyelitis
- •7.Treatment with other antimicrobials with activity against MRSA within 24hr prior to study inclusion. However, treatment failures from other therapy may be entered provided there is a positive baseline culture for MRSA.
- •8.In the case of a mixed infection where it is considered necessary to concomitantly treat with a Gram-negative agent, this agent must have no activity against MRSA.
- •9.Patients with a high probability of death within a week of study entry
- •10.Haemodialysis patients or those requiring other means of renal support for end stage renal disease.
研究者
相似试验
进行中（未招募）
1 期
Multicentre, randomised controlled clinical trial to compare minocycline plus rifampicin with linezolid against MRSA in complex skin and skin structure infections (cSSSI).Complicated Skin and Skin Structure Infections caused by Methicillin Resistant Staphylococcus AureusMedDRA version: 17.0Level: LLTClassification code 10066412Term: Staphylococcus aureus skin infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: LLTClassification code 10037633Term: Pyoderma (skin infection)System Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: PTClassification code 10066409Term: Staphylococcal skin infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001276-56-GRHellenic Institute for the Study of Sepsis225
已完成
3 期
A clinical trial to understand the effect of Vitamin C, Thiamine and hydrocortisone combination in patients with severe infectionsCTRI/2018/07/014787Amrita Institute of Medical Sciences
进行中（未招募）
1 期
Clinical trial to evaluate the patient preference for therapy with everolimus in combination with exemestane or capecitabine in combination with bevacizumab in patients with advanced (inoperable or metastatic) breast cancerEUCTR2013-005329-22-DEiOMEDICO AG77
进行中（未招募）
不适用
Australian BioEnterics Intragastric Balloon (BIB) study in obese subjects with metabolic syndromeACTRN12608000224325Allergan Australia66
已完成
不适用
A randomised comparison of two different methods of intrabronchial lignocaine delivery during flexible bronchoscopySurgeryAnaesthesiaocal anaesthetic delivery in bronchoscopyISRCTN77331907ancashire Teaching Hospitals NHS Trust (UK)100